As the novel coronavirus (COVID-19) continues to spread across the world, our analysts are constantly tracking the impact of this rapidly evolving situation on the markets and the consumer purchase behaviours. Thus, our latest estimates and analysis about the current market trends and forecast will exhaustively reflect the effects of this emerging pandemic.

Global Rare Haematology Disorders Market: By Treatment Type: Plasma Derived, Recombinant; By Disease Indication: Haemoglobin Disorders, Rare Blood Cancers, Others; By Dosage Form; By Age Group; Regional Analysis; Historical Market and Forecast (2016-2026); Competitive Landscape; Industry Events and Developments

Global Rare Haematology Disorders Market Outlook

The global rare haematology disorders market is expected to grow at a CAGR of 5.6% in the forecast period of 2021-2026.

 

High Patient Volume in North America to Aid the Market Growth of Rare Haematology Disorders

The market growth for rare haematology disorders is majorly being supported by the North America market. The region is contributing to the growth of the market as it contains a high patient volume, along with offering an option to get reimbursement for rare haematology disorder treatment products. Further, the treatment of this disorder offers a rich pipeline, and the bulk of these clinical trials are processed in the United States. The region is followed by Europe, which is expected to account for the second-largest market for rare haematology disorders across the globe. This position of Europe is owing to the rising presence of key players. Moreover, Europe offers faster approvals of orphan drugs, which decreases the time-to-market, as a result aiding the market growth.

 

Rare Haematology Disorders: Industry Definition and Segmentation

The rare haematology disorder is a set of diseases, which include anaemia-type red blood cell conditions, immuno-disorders, white blood cell dysfunctions, and other platelet-based abnormalities. These are caused when the normal process of blood formation fails, and, instead, abnormal blood cell type is produced, which results in blood cancer and other blood disorders.

On the basis of treatment type, the market is divided into:

  • Plasma Derived 
  • Recombinant

Based on disease indication, the industry can be segmented into:

  • Haemoglobin Disorders
  • Rare Blood Cancers
  • Platelet Based Disorders
  • Plasma Disorders
  • Myeloproliferative Disorders
  • Genetic Haematology Disorders
  • Others

By dosage form, the industry is classified into:

  • Oral
  • Injectable
  • Others

The industry is divided on the basis of age group into:

  • Adult (18+)
  • Paediatric (0-17)

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

Growing Rare Haemoglobin Disorders and Rare Blood Cancers to Aid the Market Growth of Rare Haematology Disorders

The market growth of rare haematology disorders is driven by the growing occurrence of rare haemoglobin disorders and rare blood cancers, which are predicted to contribute to the highest market share owing to the growing number of authorised products for these indications. Further, the rising demand for injectable dosage in the form segment is expected to propel the market growth as many of the new approvals are in injectable dosage forms.

 

Key Industry Players in the Global Rare Haematology Disorders Market

The report gives a detailed analysis of the following key players in the global rare haematology disorders market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Bristol-Myers Squibb Company
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche Ltd
  • Emmaus Medical, Inc.
  • Pfizer Inc.
  • Bayer AG
  • Others

The comprehensive EMR report provides an in-depth assessment of the industry based on the Porter's five forces model along with giving a SWOT analysis.

1    Preface
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Rare Haematology Disorders Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Rare Haematology Disorders Historical Market (2016-2020) 
    8.3    Global Rare Haematology Disorders Market Forecast (2021-2026)
    8.4    Global Rare Haematology Disorders Market by Treatment Type
        8.4.1    Plasma Derived 
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2016-2020)
            8.4.1.3    Forecast Trend (2021-2026)
        8.4.2    Recombinant
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2016-2020)
            8.4.2.3    Forecast Trend (2021-2026)
    8.5    Global Rare Haematology Disorders Market by Disease Indication
        8.5.1    Haemoglobin Disorders
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2016-2020)
            8.5.1.3    Forecast Trend (2021-2026)
        8.5.2    Rare Blood Cancers
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2016-2020)
            8.5.2.3    Forecast Trend (2021-2026)
        8.5.3    Platelet Based Disorders
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2016-2020)
            8.5.3.3    Forecast Trend (2021-2026)
        8.5.4    Plasma Disorders
            8.5.4.1    Market Share
            8.5.4.2    Historical Trend (2016-2020)
            8.5.4.3    Forecast Trend (2021-2026)
        8.5.5    Myeloproliferative Disorders
            8.5.5.1    Market Share
            8.5.5.2    Historical Trend (2016-2020)
            8.5.5.3    Forecast Trend (2021-2026)
        8.5.6    Genetic Haematology Disorders
            8.5.6.1    Market Share
            8.5.6.2    Historical Trend (2016-2020)
            8.5.6.3    Forecast Trend (2021-2026)
        8.5.7    Others
    8.6    Global Rare Haematology Disorders Market by Dosage Form
        8.6.1    Oral
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2016-2020)
            8.6.1.3    Forecast Trend (2021-2026)
        8.6.2    Injectable
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2016-2020)
            8.6.2.3    Forecast Trend (2021-2026)
        8.6.3    Others
    8.7    Global Rare Haematology Disorders Market by Age Group
        8.7.1    Adult (18+)
            8.7.1.1    Market Share
            8.7.1.2    Historical Trend (2016-2020)
            8.7.1.3    Forecast Trend (2021-2026)
        8.7.2    Pediatric (0-17)
            8.7.2.1    Market Share
            8.7.2.2    Historical Trend (2016-2020)
            8.7.2.3    Forecast Trend (2021-2026)
    8.8    Global Rare Haematology Disorders Market by Region
        8.8.1    Market Share
            8.8.1.1    North America
            8.8.1.2    Europe
            8.8.1.3    Asia Pacific
            8.8.1.4    Latin America
            8.8.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2016-2020)
        9.1.2    Forecast Trend (2021-2026)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2016-2020)
        9.2.2    Forecast Trend (2021-2026)
        9.2.3    Breakup by Country
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2016-2020)
        9.3.2    Forecast Trend (2021-2026)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2016-2020)
        9.4.2    Forecast Trend (2021-2026)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2016-2020)
        9.5.2    Forecast Trend (2021-2026)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    EMR’s Key Indicators for Demand
    10.4    EMR’s Key Indicators for Price
11    Competitive Landscape
    11.1    Market Structure
    11.2    Company Profiles
        11.2.1    Bristol-Myers Squibb Company
            11.2.1.1    Company Overview
            11.2.1.2    Product Portfolio
            11.2.1.3    Demographic Reach and Achievements
            11.2.1.4    Certifications
        11.2.2    Novo Nordisk A/S
            11.2.2.1    Company Overview
            11.2.2.2    Product Portfolio
            11.2.2.3    Demographic Reach and Achievements
            11.2.2.4    Certifications
        11.2.3    F. Hoffmann-La Roche Ltd
            11.2.3.1    Company Overview
            11.2.3.2    Product Portfolio
            11.2.3.3    Demographic Reach and Achievements
            11.2.3.4    Certifications
        11.2.4    Emmaus Medical, Inc.
            11.2.4.1    Company Overview
            11.2.4.2    Product Portfolio
            11.2.4.3    Demographic Reach and Achievements
            11.2.4.4    Certifications
        11.2.5    Pfizer Inc.
            11.2.5.1    Company Overview
            11.2.5.2    Product Portfolio
            11.2.5.3    Demographic Reach and Achievements
            11.2.5.4    Certifications
        11.2.6    Bayer AG
            11.2.6.1    Company Overview
            11.2.6.2    Product Portfolio
            11.2.6.3    Demographic Reach and Achievements
            11.2.6.4    Certifications
        11.2.7    Others
12    Industry Events and Developments

 

List of Figures and Tables

1.    Global Rare Haematology Disorders Market: Key Industry Highlights, 2016 and 2026
2.    Global Rare Haematology Disorders Historical Market: Breakup by Treatment Type (USD Billion), 2016-2020
3.    Global Rare Haematology Disorders Market Forecast: Breakup by Treatment Type (USD Billion), 2021-2026
4.    Global Rare Haematology Disorders Historical Market: Breakup by Disease Indication (USD Billion), 2016-2020
5.    Global Rare Haematology Disorders Market Forecast: Breakup by Disease Indication (USD Billion), 2021-2026
6.    Global Rare Haematology Disorders Historical Market: Breakup by Dosage Form (USD Billion), 2016-2020
7.    Global Rare Haematology Disorders Market Forecast: Breakup by Dosage Form (USD Billion), 2021-2026
8.    Global Rare Haematology Disorders Historical Market: Breakup by Age Group (USD Billion), 2016-2020
9.    Global Rare Haematology Disorders Market Forecast: Breakup by Age Group (USD Billion), 2021-2026
10.    Global Rare Haematology Disorders Historical Market: Breakup by Region (USD Billion), 2016-2020
11.    Global Rare Haematology Disorders Market Forecast: Breakup by Region (USD Billion), 2021-2026
12.    North America Rare Haematology Disorders Historical Market: Breakup by Country (USD Billion), 2016-2020
13.    North America Rare Haematology Disorders Market Forecast: Breakup by Country (USD Billion), 2021-2026
14.    Europe Rare Haematology Disorders Historical Market: Breakup by Country (USD Billion), 2016-2020
15.    Europe Rare Haematology Disorders Market Forecast: Breakup by Country (USD Billion), 2021-2026
16.    Asia Pacific Rare Haematology Disorders Historical Market: Breakup by Country (USD Billion), 2016-2020
17.    Asia Pacific Rare Haematology Disorders Market Forecast: Breakup by Country (USD Billion), 2021-2026
18.    Latin America Rare Haematology Disorders Historical Market: Breakup by Country (USD Billion), 2016-2020.
19.    Latin America Rare Haematology Disorders Market Forecast: Breakup by Country (USD Billion), 2021-2026
20.    Middle East and Africa Rare Haematology Disorders Historical Market: Breakup by Country (USD Billion), 2016-2020
21.    Middle East and Africa Rare Haematology Disorders Market Forecast: Breakup by Country (USD Billion), 2021-2026
22.    Global Rare Haematology Disorders Market Structure

Key Questions Answered in the Report

The global rare haematology disorders market is projected to grow at a CAGR of 5.6% between 2021 and 2026.

The major drivers of the industry, such as rising disposable incomes, growing incidences of rare haemoglobin disorders and rare blood cancers, rising demand for injectable dosages, and rising presence of key players, are expected to aid the market growth.

The key industry trend guiding the growth of the market includes the growing R&D activities within the industry.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The leading treatment types in the market are plasma derived and recombinant.

The major disease indications in the industry are haemoglobin disorders, rare blood cancers, platelet based disorders, plasma disorders, myeloproliferative disorders, and genetic haematology disorders, among others.

The significant dosage forms in the market are oral and injectable, among others.

The major age group segments in the industry are adult (18+) and paediatric (0-17).

The major players in the industry are Bristol-Myers Squibb Company, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Emmaus Medical, Inc., Pfizer Inc., and Bayer AG, among others.

Analyst Review

The global rare haematology disorders market is being driven by the rising incidences of rare haemoglobin disorders. Aided by the growing R&D activities, the market is expected to witness a healthy growth in the forecast period of 2021-2026, growing at a CAGR of 5.6%.

EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on treatment type, the market is bifurcated into plasma derived and recombinant. On the basis of disease indication, the industry is divided into haemoglobin disorders, rare blood cancers, platelet based disorders, plasma disorders, myeloproliferative disorders, and genetic haematology disorders, among others. By dosage form, the market is segmented into oral and injectable, among others. Based on age group, the market is bifurcated into adult (18+) and paediatric (0-17). The major regional markets for rare haematology disorders are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The key players in the above market include Bristol-Myers Squibb Company, Novo Nordisk A/S, F. Hoffmann-La Roche Ltd, Emmaus Medical, Inc., Pfizer Inc., and Bayer AG, among others.

EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$ 1999     $1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Single User License

$ 3099     $2499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Five User License

$ 4099     $3499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Corporate License

$ 5099     $4499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • Free Update in 180 Days

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

RIGHT PEOPLE

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

RIGHT METHODOLOGY

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

RIGHT PRICE

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

RIGHT SUPPORT

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

Similar Reports

Global Cancer/Tumour Profiling Market Report and Forecast 2020-2025


Global Wellness Genomics Market Report and Forecast 2020-2025



Global Soft Tissue Allografts Market Report and Forecast 2020-2025


Global Label-Free Array Systems Market Report and Forecast 2020-2025


NEWSLETTER